
    
      This is an open-label, randomized, single-dose per period, four-period, crossover study to
      evaluate relative bioavailability of decitabine in three newly formulated THU and decitabine
      combination capsules in comparison to 3 capsules of THU followed 1 hour later by 3 capsules
      of decitabine.
    
  